title: [Influence of Immunohistochemistry Scoring Criteria in Detecting EGFR Mutations].
abstract: BACKGROUND
  Appropriate immunohistochemistry (IHC) scoring criteria can guarantee the reliability of mutation detection results. Most current studies suggest that the "four-grade criterion" may be the best among all scoring systems. The aim of this study is to discuss the influence of different four-grade immunohistochemistry scoring criteria on the test results.
  
  
  METHODS
  Three different four-grade immunohistochemistry scoring criteria were respectively used to evaluate the EGFR status of 83 cases of non-small cell of lung cancer (NSCLC) samples. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), the agreement of each criterion compared with the gold standard, and whether statistical significance exists between each criterion were calculated.
  
  
  RESULTS
  No statistical difference was found among the three criteria in detecting EGFR mutations. All three criteria exhibit considerably better specificity than sensitivity. For samples with scores of "3+", PPV could reach up to 100%.
  
  
  CONCLUSIONS
  No definite best criterion is among different four-grade scoring criteria. Regardless of the kind of criterion used, the specificity of IHC method in detecting EGFR mutations is markedly better than the sensitivity. For samples with scores of "3+", mutation status can be confirmed, and samples can receive EGFR-TKI therapy directly.
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Feng
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Chang
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Diansheng
authors.initials: D
authors.lastname: Zhong
authors.affiliation: Department of Pathology, Tianjin Medical University, Tianjin 300070, China.
authors.forename: Dongbo
authors.initials: D
authors.lastname: Xu
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Ning
authors.affiliation: Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics*; D004252:DNA Mutational Analysis / Q000379:methods*; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics*; D009154:Mutation; D015203:Reproducibility of Results
chemical_list: D066246:ErbB Receptors